Background The assessment of treatment response in idiopathic pulmonary fibrosis (IPF) is
complicated by the variable clinical course. We examined the variability in the rate of …

Background Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary
fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

This post hoc analysis examined the differences in idiopathic pulmonary fibrosis disease
progression and the effects of pirfenidone in patients stratified by more preserved versus …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Background RECAP is an open-label extension study evaluating pirfenidone in patients with
idiopathic pulmonary fibrosis (IPF) who completed the Phase 3 CAPACITY program …

Background Patients with idiopathic pulmonary fibrosis (IPF) demonstrate a range of lung
function impairment. However, the efficacy of antifibrotics compared with placebo has not …

Pirfenidone is an orally administered pyridine that has orphan designation for the treatment
of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Summary Background In this retrospective Italian study, which involved all major national
interstitial lung diseases centers, we evaluated the effect of pirfenidone on disease …